Polish Adult Leukemia Group

Quick facts

Phase 3 pipeline

• A arm (CLAG-M) · Oncology
  CLAG-M is a chemotherapy regimen combining cladribine, cytarabine, and mitoxantrone designed to induce remission in acute myeloid leukemia.
• A arm (DA-90) · Oncology
  DA-90 is a monoclonal antibody targeting CD19.
• B arm (DAC) · Oncology
  DAC (daunorubicin, cytarabine, and cladribine) is a combination chemotherapy regimen that damages leukemic cell DNA and inhibits nucleotide synthesis to induce apoptosis.
• B arm (FLAG-IDA) · Oncology
  FLAG-IDA is a chemotherapy combination regimen that uses fludarabine, cytarabine, and idarubicin to induce apoptosis in leukemic cells through DNA damage and inhibition of DNA synthesis.

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Polish Adult Leukemia Group portfolio CI brief
• Polish Adult Leukemia Group pipeline updates RSS